Hydroquine 200 mg 20 tablets

Tradename

Hydroquine

Compound:

Each tablet contains:

Hydroxychloroquine sulfate 200 mg

Properties

Hydroxychloroquine has antimalarial properties, and also has anti-inflammatory and immunosuppressive effects in chronic discoid or systemic lupus erythematosus (SLE), acute and chronic rheumatoid arthritis (RA). Its mechanism of action in malaria, lupus erythematosus, and rheumatoid arthritis is not fully understood.

Hydroxychloroquine has the properties of a moderate immunosuppressant, inhibiting the synthesis of rheumatoid factor and components of the acute phase reaction. It also accumulates in leukocytes, stabilizing lysosomal membranes, and inhibits the activity of many enzymes, incl. collagenases and proteases that cause cartilage breakdown.

Indications

Malaria (with the exception of chloroquine-resistant strains of P. falciparum): prevention and relief of acute attacks of malaria caused by Plasmodium vivax, P. ovale and P. malariae, as well as susceptible strains of P. falciparum; radical treatment of malaria caused by susceptible strains of P. falciparum; rheumatoid arthritis; juvenile rheumatoid arthritis; lupus erythematosus (systemic and discoid); photodermatitis.

Dosage and administration

The optimal dosing regimen is determined by the doctor. Compliance of the dosage form of a particular drug with indications for use and dosing regimen should be strictly observed.

inside.

Only the minimum effective dose should be used.

Contraindications

Hypersensitivity to hydroxychloroquine and 4-aminoquinoline derivatives; retinopathy (including history of maculopathy); children’s age if long-term therapy is necessary (children have an increased risk of developing toxic effects); children under 6 years of age (200 mg tablets are not intended for children with an «ideal» body weight of less than 31 kg); pregnancy.

Precautionary measures:

Before starting a long course of treatment with hydroxychloroquine, a thorough examination of both eyes should be performed. The examination should include determination of visual acuity, examination of the fundus, assessment of color vision and visual fields. During therapy, such an examination should be carried out at least 1 time in 6 months.

Side effects

From the side of the hematopoietic system:

oppression of bone marrow hematopoiesis, anemia, aplastic anemia.

From the immune system: